Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. - Wikidata - awgldk - TriplyDB

Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease.

Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q37729203

about

Quality of life, religious attitude and cancer coping in a sample of Iranian patients with cancer.Application of WHOQOL-BREF in Measuring Quality of Life in Health-Care Staff.

P2860

Q35686118-CDFB9A8C-5CB1-4600-B7C5-E9804070C3E8 Q37177330-CC2548C9-8AF4-449D-9A6D-7B897234914A

P2860

Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q37729203

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@en

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@nl

type

label

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@en

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@nl

prefLabel

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@en

Effects of inhaled therapies o ...... obstructive pulmonary disease.

@nl

P1433

Q37729203-011EEE8F-80FB-4DCB-A32C-7AD951B335C2

P1476

Q37729203-0E9DB861-D747-454E-BAA6-AD01DC36C590

P2093

Q37729203-BB973FD7-0F10-433E-B4F8-357940A7CB47

P2860

Q37729203-09EA63C6-3061-45DA-B71C-6673EC045427

Q37729203-0AFD63F7-EC47-47BE-9F22-47A7DD46DDF9

Q37729203-0F04613F-B17A-4C96-B651-2A479DD783B3

Q37729203-115E8AA1-91FF-47D4-8926-ADE46EC8B61C

Q37729203-1B35592B-22C5-41D6-921B-999938511754

Q37729203-1EABF82D-F8A9-4BAB-ADBB-00442781ED69

Q37729203-2C83F846-CCA9-4FA2-B1FD-370634EDC3B9

Q37729203-35BBBE8A-0E6C-4BF2-A272-45461B87E986

Q37729203-3603E82F-0EAB-4097-A672-BEF9065DAE16

Q37729203-38B1FA9F-ADBA-4937-82A9-A4CD882BA4C5

P304

Q37729203-C7525DC8-0EE7-4F1B-9F32-27A4FC87AC96

P31

Q37729203-0523C113-E7DA-4050-ADB5-7CCD16D25F4A

P356

Q37729203-EA4A7AC3-22FE-43BC-A280-1E3268A32666

P433

Q37729203-1EC76720-5B81-4ABF-8EAD-0F11C974B50B

P478

Q37729203-516BA375-2741-4E2C-839A-EFAF303960B8

P50

Q37729203-539B24B1-07C9-4FC7-9F1B-5DD00E7E8F74

P577

Q37729203-7489B32F-5C99-4DDA-84A4-E42187436408

P698

Q37729203-5014AFFA-C6B3-4F1B-AD42-880D62B08026

P921

Q37729203-212E3613-4001-4212-BF6A-887388293C30

Q37729203-38270C99-08B1-4807-8579-569CD43EF957

P356

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Effects of inhaled therapies o ...... obstructive pulmonary disease

@en

P2093

Sabina A Antoniu

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

Development, validity and responsiveness of the Clinical COPD Questionnaire

The MOS 36-ltem Short-Form Health Survey (SF-36)

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.

A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting.

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

P304

155-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERP.10.11

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Sabina Antonela Antoniu

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20384562

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

chronic obstructive pulmonary disease